NOVO Nordisk has a new brand of semaglutide to target weight loss, Wegovy, available in Australia from this month.
Semaglutide is the same active ingredient found in Ozempic, a type 2 diabetes treatment, which has been subject to intermittent shortages since 2022.
The TGA has published a web statement about the availability of Wegovy, which includes updated advice for prescribing for the drugs Ozempic and Wegovy.
To learn more, CLICK HERE.
The above article was sent to subscribers in Pharmacy Daily's issue from 08 Aug 24
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 08 Aug 24
